Jefferies Sees Limited Impact for PTC Therapeutics (PTCT) After Sarepta's Eteplirsen was Approved

September 20, 2016 9:05 AM EDT Send to a Friend
Jefferies analyst Gena Wang sees limited impact to PTC Therapeutics (NASDAQ: PTCT) from Sarepta Therapeutics (NASDAQ: SRPT) eteplirsen approval.Wang commented ...

To continue reading this article and more like it please sign-in or join today (FREE!)

Member Login